RCS - Angle PLC - Independent Parsortix study

AngleAnnouncement

01/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240801:nRSA6696Ya&default-theme=true

RNS Number : 6696Y  Angle PLC  01 August 2024

 For immediate release  01 August 2024

 

 

ANGLE plc ("the Company")

 

INDEPENDENT PARSORTIX STUDY HIGHLIGHTS BENEFITS OF COMBINED DNA ANALYSIS IN
MELANOMA

 

Multi-analyte approach has potential to guide personalised cancer care

 

CTC mutation profiles associated with more aggressive disease

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the results of an
independent study in melanoma patients comparing gene mutations in tumour
tissue, circulating tumour DNA (ctDNA) and CTCs.

 

The study, from Dr Laura Keller's team at the Department of Tumor Biology,
University Medical Center Hamburg-Eppendorf, Germany, used the Parsortix(®)
system to isolate CTCs from melanoma patient blood samples. The CTCs were
analysed alongside tumour tissue and ctDNA samples using PCR (for gene
amplification) followed by mass spectrometry.

 

The study found a significantly wider range of potentially clinically relevant
DNA mutations in the CTCs (intact cancer cells harvested by the Parsortix
system) compared to the ctDNA samples (DNA fragments released from dead and
dying tumour cells).  Mutations were identified in CTCs but not in matched
ctDNA samples which are clinically relevant when detected in tumour tissue,
with US Food and Drug Administration approved targeted drugs available.

 

Analysis of two specific mutations which are commonly screened for in a
clinical setting for melanoma (BRAF and NRAS) identified notable differences
in the CTC samples compared to the tissue samples. The mutations identified in
CTCs but not in matched tissue samples were associated with a more aggressive
phenotype of the disease and may reflect clonal evolution of the cancer during
the time elapsed between tissue biopsy and CTC blood sample (median elapsed
time 6 months; range 0 to 41 months).

 

The authors state that the genomic analysis of CTCs has the potential to
provide additional and complementary information on clinically relevant
mutations compared to those found in tumour tissue and/or ctDNA. The authors
conclude that the integration of a multi-analyte approach has the potential to
further the evolution of personalised medicine in the field of cancer care.

 

ANGLE Chief Scientific Officer, Karen Miller commented:

"We are pleased to share this peer-reviewed publication by the University
Medical Center in Hamburg-Eppendorf, Germany. The paper demonstrates the
potential utility of CTCs enriched using the Parsortix system to provide
genomic information additional to that provided by tumour tissue or ctDNA
analysis. It highlights how mutational analysis of CTCs, isolated using the
Parsortix system, from patients with melanoma could, in the future, enable
clinicians to make more informed decisions regarding their patient's treatment
and care pathway."

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
circulating tumour cell (CTC) harvesting technology known as the Parsortix(®)
PC1 system enables complete downstream analysis of the sample including whole
cell imaging and proteomic analysis and full genomic and transcriptomic
molecular analysis.

 

ANGLE's commercial businesses are focusing on diagnostic products and clinical
services. Diagnostic products include the Parsortix(®) system and associated
consumables. The clinical services business is offered through ANGLE's
GCP-compliant laboratories in the UK.  Services include custom made assay
development and clinical trial testing for pharma.

 

Over 90 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABLGDRIXXDGSB